Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.



Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

COPD: Medications and Other Therapies

for Health Care Providers

Table 2: Medications and Other Therapies

Back to COPD Chapter

Beta-adrenergic agonists (albuterol, levalbuterol, pirbuterol)
  • Mainstay of therapy
  • eg, albuterol via nebulizer (2.5 mg) or metered-dose inhaler (MDI) (180 mcg [2 puffs]) Q2H
Anticholinergic bronchodilators (ipratropium, glycopyrrolate)
  • In addition to beta-agonists
  • eg, ipratropium via nebulizer (500 mcg) or MDI (34 mcg [2 puffs]) Q4H
  • Methylprednisolone 60-125 mg IV Q6-12H, or prednisone 40 mg PO QD
  • Treat for up to 14 days; studies show good outcomes with 9 days of treatment
  • Studies show no difference in outcomes between taper vs abrupt cessation of steroids in courses up to 14 days
  • Controversial; studies do not show convincing benefit over placebo
  • May consider for patients with increased sputum purulence AND increased sputum volume OR for patients with increased dyspnea alone
  • For patients with severe exacerbations requiring mechanical ventilation (invasive or noninvasive)
  • Predominant bacteria include Haemophilus influenza, Streptococcus pneumoniae, and Moraxella catarrhalis
  • For uncomplicated patients (FEV1>50%, no antibiotics in past 3 months, <3 exacerbations in last year): doxycycline, TMP-SMX, 2nd or 3rd generation cephalosporin, or extended-spectrum macrolide
  • For complicated patients (cardiac disease, FEV1<50%, antibiotics in past 3 months, ≥3 exacerbations in past year): amoxicillin + clavulanate or fluoroquinolone
  • Treat for 7-10 days
  • Initial dosage of 400-600 mg/day (long-acting formulation), with target blood level of 5-12 mcg/mL
Oxygen therapy
  • By nasal cannulae, Venturi masks, non-rebreather masks
  • Titrate to target pulse oxygen >90% or PaO2 >60-65 mmHg
Noninvasive positive pressure ventilation (NIPPV) in hospitalized patients
  • Such as bilevel positive airway pressure
  • Improves respiratory acidosis, decreases respiratory rate, severity of breathlessness, and length of hospital stay
  • Studies suggest that NIPPV may reduce mortality and the need for invasive ventilation
  • Consider in moderate to severe exacerbations with acidemia (pH ≤7.35) and increased work of breathing (eg, RR >25); also in patients with PaCO2 above baseline (note that patients with COPD may have stable chronic elevation in PaCO2); compare acute value with baseline

From Chronic Obstructive Pulmonary Disease
Primary Care of Veterans with HIV
Office of Clinical Public Health Programs
Veterans Health Administration, 2009